PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930113
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930113
Influenza Medication Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of influenza medication Market
The global influenza medication market plays a critical role in managing one of the most widespread and contagious infectious diseases worldwide. Influenza continues to pose a serious public health challenge due to its evolving viral strains, seasonal epidemics, and high-risk populations such as the elderly, pregnant women, and immunocompromised individuals. Growing awareness, improved diagnostics, and the launch of advanced antiviral therapies are key factors shaping the market landscape.
Market Size and Forecast
According to Fortune Business Insights, the global influenza medication market size was valued at USD 0.96 billion in 2025. The market is projected to grow to USD 0.99 billion in 2026 and reach USD 7.15 billion by 2034, registering a strong CAGR of 14.25% during the forecast period.
This robust growth is primarily attributed to the increasing frequency of influenza outbreaks, virus mutation, rising diagnosis rates, and growing adoption of next-generation antiviral drugs.
Market Overview
Influenza has shown a steady increase in global prevalence over the past few decades. Annual epidemics in countries such as the United States and recurring outbreaks across Asia and Europe significantly contribute to market expansion. According to the Centers for Disease Control and Prevention (CDC), an estimated 9.7 million influenza cases were reported in the U.S. since October 2019, highlighting the ongoing disease burden.
Although seasonal influenza vaccines are widely used, they are not always fully effective due to the genetic variability of the virus, increasing the need for effective antiviral medications.
Key Market Drivers
One of the primary drivers of the influenza medication market is increased awareness regarding the severity of influenza and its complications. Government and healthcare organizations such as the CDC and WHO actively conduct awareness campaigns, encouraging early diagnosis and treatment.
Another major driver is increased R&D activity aimed at developing novel therapeutics. Despite the growing patient population, only a limited number of FDA-approved influenza drugs are currently available, creating a large unmet treatment need. The launch of drugs such as Baloxavir Marboxil (Xofluza) has introduced new treatment options with improved efficacy.
Role of Diagnostic Advancements
Rapid Influenza Diagnostic Tests (RIDTs) have significantly influenced market growth. These tests detect influenza A and B antigens and deliver results within 5-15 minutes. Recent regulatory changes reclassifying RIDTs from Class I to Class II devices have improved their accuracy, leading to higher diagnosis rates and increased adoption of influenza medications.
Market Segmentation Analysis
By Treatment Type
Based on treatment, the market is segmented into oseltamivir phosphate, baloxavir marboxil, and others.
The oseltamivir phosphate segment dominated the market with a 57.44% share in 2026, driven by its widespread prescription and proven efficacy. However, growth is moderated due to patent expiration and generic competition.
The baloxavir marboxil segment is expected to grow at the highest CAGR, supported by recent launches in key markets such as the U.S. and Japan.
By Influenza Type
By influenza type, the market is segmented into influenza A and influenza B.
The influenza A segment accounted for 75.82% market share in 2026, owing to its high prevalence and association with major outbreaks. Influenza B also contributes to market growth during certain flu seasons.
By Route of Administration
The oral route dominated the market, accounting for 95.02% share in 2026, due to ease of administration and widespread use of drugs such as Tamiflu and Xofluza.
By Distribution Channel
The hospital pharmacies segment held the largest market share, supported by diagnosis-based prescriptions. Retail pharmacies ranked second, while online pharmacies are expected to witness the highest CAGR due to growing digital adoption.
Regional Analysis
North America dominated the influenza medication market with a 59.56% share in 2025 and generated USD 0.59 billion in revenue in 2026. The U.S. market alone is projected to reach USD 0.55 billion by 2026.
The Asia-Pacific region is expected to register the fastest growth, with Japan reaching USD 0.07 billion, China USD 0.05 billion, and India USD 0.02 billion by 2026. Europe is also witnessing rising influenza activity, supporting steady market growth.
Competitive Landscape
The market is led by key players such as Genentech, Inc., Shionogi & Co., Ltd., GlaxoSmithKline plc, Seqirus (CSL), and BioCryst Pharmaceuticals, Inc. The presence of generics makes the market mature and competitive, creating barriers for new entrants.
Conclusion
In conclusion, the global influenza medication market is poised for significant growth from USD 0.96 billion in 2025 to USD 7.15 billion by 2034, driven by rising influenza prevalence, improved diagnostics, strong R&D pipelines, and growing awareness initiatives. While generic competition remains a challenge, the introduction of advanced antiviral therapies and expanding healthcare access worldwide will continue to support long-term market expansion.
Segmentation By Treatment
- Baloxavir marboxil
- Oseltamivir phosphate
- Others
By Influenza Type
- Influenza A
- Influenza B
By Route of Administration
- Oral
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Geography
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Overview of Influenza Epidemiology
- 4.2. Analysis of Disease Burden of Influenza, By Key Regions
- 4.3. New Product Launches
- 4.4. Pipeline Analysis
- 4.5. Analysis of the Impact of the Launch of Generics on the Influenza Medication Market
- 4.6. Key Industry Developments
5. Global Influenza Medication Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Treatment
- 5.2.1. Baloxavir marboxil
- 5.2.2. Oseltamivir phosphate
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Influenza Type
- 5.3.1. Influenza A
- 5.3.2. Influenza B
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Oral
- 5.4.2. Others
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Retail Pharmacies
- 5.5.3. Online Pharmacies
- 5.5.4. Others
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Influenza Medication Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis - By Treatment
- 6.2.1. Baloxavir marboxil
- 6.2.2. Oseltamivir phosphate
- 6.2.3. Others
- 6.3. Market Analysis - By Influenza Type
- 6.3.1. Influenza A
- 6.3.2. Influenza B
- 6.4. Market Analysis - By Route of Administration
- 6.4.1. Oral
- 6.4.2. Others
- 6.5. Market Analysis - By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Retail Pharmacies
- 6.5.3. Online Pharmacies
- 6.5.4. Others
- 6.6. Market Analysis - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Influenza Medication Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis - By Treatment
- 7.2.1. Baloxavir marboxil
- 7.2.2. Oseltamivir phosphate
- 7.2.3. Others
- 7.3. Market Analysis - By Influenza Type
- 7.3.1. Influenza A
- 7.3.2. Influenza B
- 7.4. Market Analysis - By Route of Administration
- 7.4.1. Oral
- 7.4.2. Others
- 7.5. Market Analysis - By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Retail Pharmacies
- 7.5.3. Online Pharmacies
- 7.5.4. Others
- 7.6. Market Analysis - By Country/Sub-Region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Influenza Medication Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis - By Treatment
- 8.2.1. Baloxavir marboxil
- 8.2.2. Oseltamivir phosphate
- 8.2.3. Others
- 8.3. Market Analysis - By Influenza Type
- 8.3.1. Influenza A
- 8.3.2. Influenza B
- 8.4. Market Analysis - By Route of Administration
- 8.4.1. Oral
- 8.4.2. Others
- 8.5. Market Analysis - By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Retail Pharmacies
- 8.5.3. Online Pharmacies
- 8.5.4. Others
- 8.6. Market Analysis - By Country/Sub-Region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Influenza Medication Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis - By Treatment
- 9.2.1. Baloxavir marboxil
- 9.2.2. Oseltamivir phosphate
- 9.2.3. Others
- 9.3. Market Analysis - By Influenza Type
- 9.3.1. Influenza A
- 9.3.2. Influenza B
- 9.4. Market Analysis - By Route of Administration
- 9.4.1. Oral
- 9.4.2. Others
- 9.5. Market Analysis - By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Retail Pharmacies
- 9.5.3. Online Pharmacies
- 9.5.4. Others
- 9.6. Market Analysis - By Country/Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Influenza Medication Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Key Findings / Summary
- 10.2. Market Analysis - By Treatment
- 10.2.1. Baloxavir marboxil
- 10.2.2. Oseltamivir phosphate
- 10.2.3. Others
- 10.3. Market Analysis - By Influenza Type
- 10.3.1. Influenza A
- 10.3.2. Influenza B
- 10.4. Market Analysis - By Route of Administration
- 10.4.1. Oral
- 10.4.2. Others
- 10.5. Market Analysis - By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
- 10.5.4. Others
- 10.6. Market Analysis - By Country/ Sub-Region
- 10.6.1. GCC Countries
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2025)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis - Major Players
- 11.5. Company Profiles
- 11.5.1. Genentech, Inc.
- 11.5.1.1. Overview,
- 11.5.1.2. Products & Services,
- 11.5.1.3. SWOT Analysis,
- 11.5.1.4. Recent Developments,
- 11.5.1.5. Strategies,
- 11.5.1.6. Financials (Based On Availability)
- 11.5.2. Shionogi & Co., Ltd.
- 11.5.2.1. Overview,
- 11.5.2.2. Products & Services,
- 11.5.2.3. SWOT Analysis,
- 11.5.2.4. Recent Developments,
- 11.5.2.5. Strategies,
- 11.5.2.6. Financials (Based On Availability)
- 11.5.3. Seqirus (CSL)
- 11.5.3.1. Overview,
- 11.5.3.2. Products & Services,
- 11.5.3.3. SWOT Analysis,
- 11.5.3.4. Recent Developments,
- 11.5.3.5. Strategies,
- 11.5.3.6. Financials (Based On Availability)
- 11.5.4. BIOCRYST PHARMACEUTICALS, INC.
- 11.5.4.1. Overview,
- 11.5.4.2. Products & Services,
- 11.5.4.3. SWOT Analysis,
- 11.5.4.4. Recent Developments,
- 11.5.4.5. Strategies,
- 11.5.4.6. Financials (Based On Availability)
- 11.5.5. GlaxoSmithKline plc
- 11.5.5.1. Overview,
- 11.5.5.2. Products & Services,
- 11.5.5.3. SWOT Analysis,
- 11.5.5.4. Recent Developments,
- 11.5.5.5. Strategies,
- 11.5.5.6. Financials (Based On Availability)
- 11.5.6. Lupin Limited
- 11.5.6.1. Overview,
- 11.5.6.2. Products & Services,
- 11.5.6.3. SWOT Analysis,
- 11.5.6.4. Recent Developments,
- 11.5.6.5. Strategies,
- 11.5.6.6. Financials (Based On Availability)
- 11.5.7. Teva Pharmaceutical Industries Ltd.
- 11.5.7.1. Overview,
- 11.5.7.2. Products & Services,
- 11.5.7.3. SWOT Analysis,
- 11.5.7.4. Recent Developments,
- 11.5.7.5. Strategies,
- 11.5.7.6. Financials (Based On Availability)
- 11.5.8. Zydus Pharmaceuticals, Inc. (Zydus Cadila)
- 11.5.8.1. Overview,
- 11.5.8.2. Products & Services,
- 11.5.8.3. SWOT Analysis,
- 11.5.8.4. Recent Developments,
- 11.5.8.5. Strategies,
- 11.5.8.6. Financials (Based On Availability)
- 11.5.9. Amneal Pharmaceuticals LLC
- 11.5.9.1. Overview,
- 11.5.9.2. Products & Services,
- 11.5.9.3. SWOT Analysis,
- 11.5.9.4. Recent Developments,
- 11.5.9.5. Strategies,
- 11.5.9.6. Financials (Based On Availability)
- 11.5.10. Macleods Pharmaceuticals Ltd.
- 11.5.10.1. Overview,
- 11.5.10.2. Products & Services,
- 11.5.10.3. SWOT Analysis,
- 11.5.10.4. Recent Developments,
- 11.5.10.5. Strategies,
- 11.5.10.6. Financials (Based On Availability)
- 11.5.11. Alvogen
- 11.5.11.1. Overview,
- 11.5.11.2. Products & Services,
- 11.5.11.3. SWOT Analysis,
- 11.5.11.4. Recent Developments,
- 11.5.11.5. Strategies,
- 11.5.11.6. Financials (Based On Availability)
- 11.5.12. Others
- 11.5.12.1. Overview,
- 11.5.12.2. Products & Services,
- 11.5.12.3. SWOT Analysis,
- 11.5.12.4. Recent Developments,
- 11.5.12.5. Strategies,
- 11.5.12.6. Financials (Based On Availability)
- 11.5.1. Genentech, Inc.
12. Strategic Recommendations
List of Tables
- Table 1: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 2: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
- Table 3: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 4: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 5: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
- Table 6: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 7: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
- Table 8: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 10: North America Influenza Medication Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
- Table 11: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 12: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
- Table 13: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 14: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 15: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 17: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
- Table 18: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 19: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 20: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 22: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
- Table 23: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 24: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 25: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
- Table 27: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
- Table 28: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
- Table 29: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
- Table 30: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Influenza Medication Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
- Figure 2: Global Influenza Medication Market Value Share (%), by Treatment, 2025-2034
- Figure 3: Global Influenza Medication Market Forecast (US$ Mn), by Baloxavir marboxil, 2021-2034
- Figure 4: Global Influenza Medication Market Forecast (US$ Mn), by Oseltamivir phosphate, 2021-2034
- Figure 5: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 6: Global Influenza Medication Market Value Share (%), by Influenza Type, 2025-2034
- Figure 7: Global Influenza Medication Market Forecast (US$ Mn), by Influenza A, 2021-2034
- Figure 8: Global Influenza Medication Market Forecast (US$ Mn), by Influenza B, 2021-2034
- Figure 9: Global Influenza Medication Market Value Share (%), by Route of Administration, 2025-2034
- Figure 10: Global Influenza Medication Market Forecast (US$ Mn), by Oral, 2021-2034
- Figure 11: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 12: Global Influenza Medication Market Value Share (%), by Distribution Channel, 2025-2034
- Figure 13: Global Influenza Medication Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
- Figure 14: Global Influenza Medication Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
- Figure 15: Global Influenza Medication Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
- Figure 16: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
- Figure 17: Global Influenza Medication Market Value (US$ Mn), by Region, 2025-2034
- Figure 18: North America Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
- Figure 19: North America Influenza Medication Market Value Share (%), by Treatment, 2025
- Figure 20: North America Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
- Figure 21: North America Influenza Medication Market Value Share (%), by Influenza Type, 2025
- Figure 22: North America Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
- Figure 23: North America Influenza Medication Market Value Share (%), by Route of Administration, 2025
- Figure 24: North America Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
- Figure 25: North America Influenza Medication Market Value Share (%), by Distribution Channel, 2025
- Figure 26: North America Influenza Medication Market Value (US$ Mn), By Country, 2025-2034
- Figure 27: North America Influenza Medication Market Value Share (%), By Country, 2025
- Figure 28: Europe Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
- Figure 29: Europe Influenza Medication Market Value Share (%), by Treatment, 2025
- Figure 30: Europe Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
- Figure 31: Europe Influenza Medication Market Value Share (%), by Influenza Type, 2025
- Figure 32: Europe Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
- Figure 33: Europe Influenza Medication Market Value Share (%), by Route of Administration, 2025
- Figure 34: Europe Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
- Figure 35: Europe Influenza Medication Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Europe Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
- Figure 37: Europe Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
- Figure 38: Asia Pacific Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
- Figure 39: Asia Pacific Influenza Medication Market Value Share (%), by Treatment, 2025
- Figure 40: Asia Pacific Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
- Figure 41: Asia Pacific Influenza Medication Market Value Share (%), by Influenza Type, 2025
- Figure 42: Asia Pacific Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
- Figure 43: Asia Pacific Influenza Medication Market Value Share (%), by Route of Administration, 2025
- Figure 44: Asia Pacific Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
- Figure 45: Asia Pacific Influenza Medication Market Value Share (%), by Distribution Channel, 2025
- Figure 46: Asia Pacific Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
- Figure 47: Asia Pacific Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
- Figure 48: Latin America Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
- Figure 49: Latin America Influenza Medication Market Value Share (%), by Treatment, 2025
- Figure 50: Latin America Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
- Figure 51: Latin America Influenza Medication Market Value Share (%), by Influenza Type, 2025
- Figure 52: Latin America Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
- Figure 53: Latin America Influenza Medication Market Value Share (%), by Route of Administration, 2025
- Figure 54: Latin America Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
- Figure 55: Latin America Influenza Medication Market Value Share (%), by Distribution Channel, 2025
- Figure 56: Latin America Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
- Figure 57: Latin America Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
- Figure 58: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
- Figure 59: Middle East & Africa Influenza Medication Market Value Share (%), by Treatment, 2025
- Figure 60: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
- Figure 61: Middle East & Africa Influenza Medication Market Value Share (%), by Influenza Type, 2025
- Figure 62: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
- Figure 63: Middle East & Africa Influenza Medication Market Value Share (%), by Route of Administration, 2025
- Figure 64: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
- Figure 65: Middle East & Africa Influenza Medication Market Value Share (%), by Distribution Channel, 2025
- Figure 66: Middle East & Africa Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
- Figure 67: Middle East & Africa Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Influenza Medication Market Share (%), By Company, 2025
